Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

about

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

Item

http://www.wikidata.org/entity/Q53735971

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

@en

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

@nl

type

Item

label

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

@en

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

@nl

prefLabel

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

@en

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

@nl

P1476

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma

@en

P2093

Anita P Price

http://www.w3.org/2001/XMLSchema#string

Brian H Kushner

http://www.w3.org/2001/XMLSchema#string

Michael P LaQuaglia

http://www.w3.org/2001/XMLSchema#string

Rachel Glincher

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.

Management of bevacizumab-associated bowel perforation: a case series and review of the literature.

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.

Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).

Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.

P304

e394-e396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MPH.0000000000000940

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shakeel Modak

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28816801

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5812839

http://www.w3.org/2001/XMLSchema#string